Drug interactions
Idecabtagene vicleucel + Trastuzumab
Severity: Moderate
Idecabtagene vicleucel and Trastuzumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Idecabtagene vicleucel is a BCMA-directed CAR T-cell product given after lymphodepleting chemotherapy and is associated with cytopenias and infections. Trastuzumab has limited immunosuppressive activity, so any added infection risk is probably small. Concurrent use is unusual and has not been studied.
What this interaction means in plain words
Idecabtagene vicleucel and Trastuzumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Idecabtagene vicleucel belongs to Oncology; Trastuzumab belongs to Oncology.
Why it happens
Possible additive effects on immune and hematologic function; the interaction is largely theoretical.
What to do
Review the need for trastuzumab around CAR T infusion and monitor blood counts and for infection. Follow the CAR T product's guidance on concomitant therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Idecabtagene vicleucel and Trastuzumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Trastuzumab
Other interactions of Idecabtagene vicleucel
Frequently asked questions
Can I take Idecabtagene vicleucel with Trastuzumab?
MediHelp rates the interaction as moderate. Idecabtagene vicleucel and Trastuzumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Idecabtagene vicleucel is a BCMA-directed CAR T-cell product given after lymphodepleting chemotherapy and is associated with cytopenias and infections. Trastuzumab has limited immunosuppressive activity, so any added infection risk is probably small. Concurrent use is unusual and has not been studied.
How serious is the interaction between Idecabtagene vicleucel and Trastuzumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Review the need for trastuzumab around CAR T infusion and monitor blood counts and for infection. Follow the CAR T product's guidance on concomitant therapy.
What other medicines interact with Trastuzumab?
MediHelp also lists interactions of Trastuzumab with, for example, Daunorubicin, Doxorubicin liposomal, Doxorubicin. The full list is on the Trastuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
